What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
Health Expectations · 2025
DOI: 10.1111/hex.70251 ↗Kurz gefasst
Scoping Review in der Zeitschrift Health Expectations, 2025. Verfasst von Sam Febrey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, St Lukes Campus, Exeter, Devon, UK. Hauptthemen laut MEDLINE: Attitude of Health Personnel, Caregivers, Glucagon-Like Peptide-1 Receptor Agonists, Patients. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported NIHR Evidence Synthesis Programme (NIHR153420)..
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are a pharmacological treatment option for both diabetes and weight loss. Qualitative evidence is vital in providing greater understanding of patients, practitioners and carers experience of taking or delivering GLP‐1 RAs. This evidence can inform the current or future configuration and delivery of services. We conducted a scoping review to better understand the quantity, nature and key characteristics of qualitative primary evidence which explores the experiences, views and perceptions of patients, carers and clinicians regarding the use of GLP‐1 RAs.
Methods
Four bibliographic databases were searched on 10 July 2024: MEDLINE, APA PsycInfo via Ovid, CINAHL Ultimate via EBSCOhost, ProQuest Dissertations and Theses Global via ProQuest. We also searched Google Scholar, two clinical trials registries, the pre‐print server medRxiv and conducted citation searches. We sought qualitative research about the experiences of patients, carers and practitioners about any aspect of taking or prescribing GLP‐1RAs, for any indication. Study selection and data extraction were performed by two independent reviewers. The included studies were collated, and their characteristics were described.
Results
After de‐duplication 1545 titles and abstracts were screened for relevance, with 77 full‐text articles assessed for eligibility, resulting in 25 included studies. More studies were focused on type 2 diabetes ( n = 12) than weight loss ( n = 9) or any indication ( n = 4). The experiences of carers were not represented. No one area of experience (e.g. different indications or viewpoints) was well represented, either due to the absence or narrow focus of studies or lack of an in‐depth analytical approach.
Conclusion
Whilst primary qualitative evidence exploring patient and clinician experience of GLP‐1 RAs was identified in this scoping review, the findings highlight a need for more robust qualitative research to be conducted across all user groups, in particular involving carers, and especially for the indication of weight loss within service settings. This evidence gap needs to be urgently addressed to ensure GLP‐1 RAs are appropriately prescribed and patients and carers receive support from services suited to their needs. Patient or Public Contribution Seventeen public collaborators contributed to the search by suggesting additional search terms, helping define the population for inclusion and contributing to protocol development. Their thoughts on the findings of the review helped form the basis for the discussion of this paper.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, St Lukes Campus, Exeter, Devon, UK.
- NIHR Applied Research Collaboration South West Peninsula (PenARC), University of Exeter Medical School, University of Exeter, St Lukes Campus, Exeter, Devon, UK.
ORCID-Profile: Sam Febrey, Michael Nunns, Jill Buckland, Rebecca Abbott, Rebecca Whear, Kate Boddy, G J Melendez-Torres, Jo Thompson Coon, Liz Shaw
Förderung
- This study was supported NIHR Evidence Synthesis Programme (NIHR153420).
Zitieren
APA
Febrey, S., Nunns, M., Buckland, J., Abbott, R., Bethel, A., Whear, R., Boddy, K., Melendez-Torres, G. J., Coon, J. T., & Shaw, L. (2025). What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review. Health Expectations. https://doi.org/10.1111/hex.70251
Vancouver
Febrey S, Nunns M, Buckland J, Abbott R, Bethel A, Whear R, et al. What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review. Health Expectations. 2025. doi:10.1111/hex.70251
BibTeX
@article{Febrey2025,
author = {Febrey, Sam and Nunns, Michael and Buckland, Jill and Abbott, Rebecca and Bethel, Alison and Whear, Rebecca and Boddy, Kate and Melendez-Torres, G J and Coon, Jo Thompson and Shaw, Liz},
title = {What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review},
journal = {Health Expectations},
year = {2025},
doi = {10.1111/hex.70251}
}
EUVIMED